Fig. 7: Epigenetic control of CEACAM6 expression in lung cancer cells. | npj Precision Oncology

Fig. 7: Epigenetic control of CEACAM6 expression in lung cancer cells.

From: Cytokine and epigenetic regulation of CEACAM6 mediates EGFR-driven signaling and drug response in lung adenocarcinoma

Fig. 7

A ChIP-seq analysis from the SRX1528527 and SRX2636288 database assessing the H3K27ac signal around the CEACAM6 loci in EGFR-mutant HCC827 and PC9 lung cancer cells. B ChIP-seq analysis evaluating the H3K27ac signal at indicated regions of the CEACAM6 locus in (left) HCC827 versus HCC827GR and (right) A549 treated with or without TGF-β (1 ng/mL) for 3 weeks. *P < 0.05; **P < 0.01; ***P < 0.001; NS, non-significant. C qRT-PCR analysis (left) evaluating CEACAM6 expression in HCC827 cells treated with or without HDAC1/2 inhibitor romidepsin (HDACi, 1 nM) for 3 weeks. Clonogenic assay (right) assessing the growth of romidepsin-treated HCC827 and parental cells in the presence of gefitinib (100 nM) for 14 days. D qRT-PCR analysis assessing CDH1 and VIM expression in HCC827 cells treated with or without romidepsin (HDACi, 1 nM) for 3 weeks. E qRT-PCR analysis evaluating TGF-β family member and receptor gene expression in HCC827 cells treated with or without romidepsin (HDACi, 1 nM) for 3 weeks (left). F qRT-PCR analysis assessing CEACAM6, CDH1, and VIM expression in HCC827 cells pretreated with romidepsin (HDACi, 1 nM) for 3 weeks, followed by further treatment with or without TGF-β receptor inhibitor SB-431542 (SB, 5 μM) for 3 weeks.

Back to article page